Taysha Gene Therapies, Inc.
TSHANasdaq
$5.96
↓ -0.2%Jul 17 close · end-of-day
Price
1Y↑ +134.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.2B
Enterprise Value
$2.0B
P/E
—
P/S
292.5
P/B
10.3
EV/EBITDA
—
PEG
—
FCF Yield
-5.1%
Dividend Yield
—
Revenue (TTM)
$7.5M
Net Income (TTM)
-$129.9M
Free Cash Flow (TTM)
-$112.3M
Gross Margin
—
Operating Margin
-1774.4%
Net Margin
-1738.4%
ROE
-61.3%
ROIC
—
Debt / Equity
0.2
Net Cash
$227.6M
Return 1Y
+130.1%
Company profile
Taysha Gene Therapies, Inc. focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company was incorporated in 2019 and is based in Dallas, Texas.
- CEO
- R. A. Session
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 180
- Headquarters
- Texas
- Website
- tayshagtx.com
Management & directors
- Nagendran SukumarPresident and Head of R&D
- Alam KamranCHIEF FINANCIAL OFFICER
- Nolan Sean P.Chief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
TSHA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00↓ -100.0%
Diluted EPS-$0.12↑ +50.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $2.5M | $15.5M | $8.3M | $9.8M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$43.0M | -$173.3M | -$162.4M | -$72.4M | -$91.5M | -$110.5M |
| Net income | -$60.0M | -$174.5M | -$166.0M | -$111.6M | -$89.3M | -$109.0M |
| Diluted EPS | — | -$4.64 | -$3.78 | -$0.96 | -$0.36 | -$0.34 |
| Operating cash flow | -$30.7M | -$117.0M | -$88.4M | -$73.0M | -$81.2M | -$93.1M |
| Free cash flow | -$30.8M | -$132.3M | -$109.0M | -$76.9M | -$81.6M | -$93.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | -6492.7% | -468.8% | -1097.6% | -1130.6% |
| Net margin | — | — | -6635.3% | -722.1% | -1071.6% | -1115.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $1.8M | $2.0M | $2.3M | $2.0M | $0.00 | $5.5M | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$21.3M | -$25.9M | -$19.9M | -$21.4M | -$26.8M | -$34.0M | -$28.3M | -$43.5M |
| Net income | -$20.9M | -$25.5M | -$18.8M | -$21.5M | -$26.9M | -$32.7M | -$27.9M | -$42.4M |
| Diluted EPS | -$0.09 | -$0.10 | -$0.07 | -$0.08 | -$0.09 | -$0.09 | -$0.08 | -$0.12 |
| Operating cash flow | -$21.5M | -$21.6M | -$18.3M | -$22.0M | -$20.2M | -$24.2M | -$26.7M | -$40.9M |
| Free cash flow | -$21.7M | -$21.6M | -$18.3M | -$22.4M | -$20.2M | -$24.3M | -$27.0M | -$40.9M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -1915.4% | -1448.4% | -985.8% | -930.5% | -1347.1% | — | -516.0% | — |
| Net margin | -1882.0% | -1427.5% | -929.0% | -935.2% | -1353.6% | — | -507.8% | — |
Company news
Jul 15, 2026
Jun 25, 2026
Jun 22, 2026
- 28d agoTaysha Advances Rett Syndrome Programme as Pivotal Trial Enrollment Completes (TSHA)investorshub.advfn.com
- 28d agoTaysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndromefinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-10 | Nagendran Sukumar· President and Head of R&D | Sale | 200,000 | $6.24 | $1.2M | filing |
| 2026-06-01 | Stalfort Sean | Award | 21,335 | $0.00 | $0.00 | filing |
| 2026-06-01 | DONENBERG PHILIP B | Award | 21,335 | $0.00 | $0.00 | filing |
| 2026-06-01 | Long Alison S | Award | 21,335 | $0.00 | $0.00 | filing |
| 2026-06-01 | Sepp-Lorenzino Laura | Award | 21,335 | $0.00 | $0.00 | filing |
| 2026-04-10 | Nagendran Sukumar· President and Head of R&D | Sale | 200,000 | $4.46 | $892,000.00 | filing |
| 2026-04-10 | Nagendran Sukumar· President and Head of R&D | Option exercise | 19,021 | $1.71 | $32,525.91 | filing |
| 2026-02-04 | Alam Kamran· CHIEF FINANCIAL OFFICER | Sale | 1,655 | $4.52 | $7,480.60 | filing |
| 2026-01-26 | Nolan Sean P.· Chief Executive Officer | Sale | 41,312 | $4.61 | $190,448.32 | filing |
| 2026-01-26 | Nagendran Sukumar· President and Head of R&D | Sale | 26,918 | $4.61 | $124,091.98 | filing |
| 2026-01-26 | Alam Kamran· CHIEF FINANCIAL OFFICER | Sale | 23,849 | $4.61 | $109,943.89 | filing |
| 2026-01-23 | Nolan Sean P.· Chief Executive Officer | Sale | 136,789 | $4.75 | $649,747.75 | filing |
| 2026-01-23 | Nagendran Sukumar· President and Head of R&D | Sale | 89,132 | $4.75 | $423,377.00 | filing |
| 2026-01-23 | Alam Kamran· CHIEF FINANCIAL OFFICER | Sale | 78,968 | $4.75 | $375,098.00 | filing |
| 2026-01-12 | Nagendran Sukumar· President and Head of R&D | Sale | 200,000 | $4.71 | $942,000.00 | filing |
| 2026-01-12 | Nagendran Sukumar· President and Head of R&D | Option exercise | 88,676 | $1.71 | $151,635.96 | filing |
| 2026-01-12 | Nagendran Sukumar· President and Head of R&D | Option exercise | 111,324 | $0.70 | $77,804.34 | filing |
| 2026-01-12 | Nolan Sean P.· Chief Executive Officer | Award | 1,008,000 | $0.00 | $0.00 | filing |
| 2026-01-12 | Nagendran Sukumar· President and Head of R&D | Award | 427,000 | $0.00 | $0.00 | filing |
| 2026-01-12 | Alam Kamran· CHIEF FINANCIAL OFFICER | Award | 359,000 | $0.00 | $0.00 | filing |
| 2025-12-01 | Nagendran Sukumar· President and Head of R&D | Sale | 260,047 | $4.51 | $1.2M | filing |
| 2025-12-01 | Nagendran Sukumar· President and Head of R&D | Option exercise | 260,047 | $1.71 | $444,680.37 | filing |
| 2025-11-28 | Nagendran Sukumar· President and Head of R&D | Sale | 110,125 | $4.75 | $523,093.75 | filing |
| 2025-11-28 | Nagendran Sukumar· President and Head of R&D | Option exercise | 39,953 | $1.71 | $68,319.63 | filing |
| 2025-11-28 | Nagendran Sukumar· President and Head of R&D | Option exercise | 70,172 | $0.70 | $49,043.21 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.